ETPrime

Parmax Pharma Share Price

  • 40.810.00 (0.00%)
  • Volume: 5
BSE
  • Closed
  • Last Updated On: 25 Jun, 2025, 03:30 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Parmax Pharma Share Price
  • 40.810.00 (0.00%)
  • Volume: 5
Advertisment

Parmax Pharma share price insights

  • Company's annual revenue growth of 154.42% outperformed its 3 year CAGR of 15.37%. (Source: Standalone Financials)

  • Company has spent 2.08% of its operating revenues towards interest expenses and 10.6% towards employee cost in the year ending Mar 31, 2025. (Source: Standalone Financials)

  • Parmax Pharma Ltd. share price remain unchanged from its previous close of Rs 40.81. Parmax Pharma Ltd. stock last traded price is 40.81

    Share PriceValue
    Today/Current/Last-40.81
    Previous Day-40.81

InsightsParmax Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		-7.29
    EPS - TTM
    (₹)    		-5.60
    MCap
    (₹ Cr.)    		15.27
    Sectoral MCap Rank
    		165
    PB Ratio
    (x)    		-7.74
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		10.00
    Beta

    Beta

    1 Month0.00
    3 Months0.00
    6 Months0.00
    1 Year0.03
    3 Years-

    		0.00
    VWAP
    (₹)    		40.81
    52W H/L
    (₹)
    55.02 / 28.70

    Parmax Pharma Share Price Returns

    1 Day0.0%
    1 Week18.29%
    1 Month-7.98%
    3 Months-4.98%
    1 Year36.76%
    3 Years37.64%
    5 Years29.56%

    ET Stock ScreenersTop Score Companies

    Check whether Parmax Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Parmax Pharma News & Analysis

    View all Parmax Pharma Share News & Announcements

    Parmax Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Parmax Pharma Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Parmax Pharma Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 154.42% outperformed its 3 year CAGR of 15.37%. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent 2.08% of its operating revenues towards interest expenses and 10.6% towards employee cost in the year ending Mar 31, 2025. (Source: Standalone Financials)
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income4.736.309.397.824.27
      Total Income Growth (%)-24.92-32.9720.0683.17219.20
      Total Expenses6.296.599.487.705.46
      Total Expenses Growth (%)-4.54-30.5523.1540.8986.21
      EBIT-1.56-0.29-0.090.12-1.19
      EBIT Growth (%)---170.54--
      Profit after Tax (PAT)-1.49-0.39-0.220.01-1.45
      PAT Growth (%)---1,862.55--
      EBIT Margin (%)-32.96-4.58-0.941.60-27.93
      Net Profit Margin (%)-31.62-6.27-2.310.16-33.95
      Basic EPS (₹)-4.00-1.05-0.580.03-3.88
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue28.2411.1015.4618.3126.29
      Total Revenue Growth (%)154.42-28.21-15.56-30.3525.02
      Total Expenses29.5716.7615.4218.0125.08
      Total Expenses Growth (%)76.448.69-14.40-28.2023.56
      Profit after Tax (PAT)-2.09-5.78-0.100.140.75
      PAT Growth (%)---173.54-81.2475.99
      Operating Profit Margin (%)-2.61-45.542.693.775.96
      Net Profit Margin (%)-7.42-52.28-0.670.772.87
      Basic EPS (₹)-5.60-11.33-0.280.382.02

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Profit & Loss Statement are available.

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets18.7515.3317.6117.9722.73
      Total Assets Growth (%)22.31-12.95-2.00-20.947.93
      Total Liabilities20.7415.2611.7612.0216.91
      Total Liabilities Growth (%)35.9129.76-2.16-28.925.69
      Total Equity-1.990.075.865.965.82
      Total Equity Growth (%)-2,942.86-98.81-1.682.4115.02
      Current Ratio (x)0.770.631.050.900.92
      Total Debt to Equity (x)-3.8783.260.760.760.93
      Contingent Liabilities0.00-1.001.00-

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Balance Sheet are available.

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 0.7 cr for investing activities which is an YoY decrease of 55.8%. (Source: Standalone Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities-0.66-0.190.330.753.53
      Net Cash used in Investing Activities-0.70-1.59-0.94-1.53-3.15
      Net Cash flow from Financing Activities1.401.43-0.04-0.910.40
      Net Cash Flow0.04-0.35-0.65-1.690.78
      Closing Cash & Cash Equivalent0.090.060.411.052.55
      Closing Cash & Cash Equivalent Growth (%)57.92-85.94-61.41-58.6044.07
      Total Debt/ CFO (x)-11.74-31.0713.456.041.54

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Cash Flow Statement are available.

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)0.00-8,146.36-1.772.3712.96
      Return on Capital Employed (%)-12.90-82.273.966.4613.60
      Return on Assets (%)-11.16-37.69-0.590.783.31
      Interest Coverage Ratio (x)0.50-5.346.226.794.41
      Asset Turnover Ratio (x)1.660.670.870.90115.29
      Price to Earnings (x)-8.98-2.19-131.58129.8720.96
      Price to Book (x)-9.46179.122.313.052.72
      EV/EBITDA (x)89.79-5.587.678.265.33
      EBITDA Margin (%)1.04-30.0514.8714.3613.37

      No reported Financial Ratios are available.

    Financial InsightsParmax Pharma

    • Income (P&L)
    • Cash Flow

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 154.42% outperformed its 3 year CAGR of 15.37%. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent 2.08% of its operating revenues towards interest expenses and 10.6% towards employee cost in the year ending Mar 31, 2025. (Source: Standalone Financials)

      • Decrease in Cash from Investing

        Company has used Rs 0.7 cr for investing activities which is an YoY decrease of 55.8%. (Source: Standalone Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Parmax Pharma Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Parmax Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Parmax Pharma-7.29-7.670.00-12.90-11.1615.37-2.61-7.42-5.600.77-3.87-11.74
          Ishita Drugs28.002.258.0411.265.322.578.185.782.902.770.36-1.07
          Zenlabs Ethica 80.352.072.5810.820.66-9.302.630.520.411.331.143.10
          Norris Medicine-15.31-1.270.00-20.17-8.96-14.53-12.68-21.26-1.240.62-1.4572.30
          Chemo Pharma51.534.80-39.44-35.51-37.44-7.650.000.00-9.6628.820.000.00
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Desh Rakshak
          • Colinz Labs
          • Kamron Labs.
          • Unjha Form
          • Beryl Drugs

          Choose from Stocks

            See All Parameters

          Peers InsightsParmax Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Parmax Pharma Shareholding Pattern

            • Loading...
              Showing Parmax Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters30.8030.8030.8030.80
              Pledge0.000.000.000.00
              FII0.000.000.000.00
              DII0.000.000.000.00
              Mutual Funds0.000.000.000.00
              Others69.2069.2069.2069.20
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters11,52,45030.80 %0.00
              Pledge00.00 %0.00
              Others25,88,85069.20 %0.00

            Parmax Pharma MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Parmax Pharma News Parmax Pharma Quarterly Results Parmax Pharma Dividend Parmax Pharma Q1 ResultsParmax Pharma Q2 ResultsParmax Pharma Q3 ResultsParmax Pharma Q4 Results

            Parmax Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 30, 2025May 21, 2025Board MeetingAudited Results
              Feb 14, 2025Feb 06, 2025Board MeetingQuarterly Results
              Nov 14, 2024Nov 06, 2024Board MeetingQuarterly Results
              Sep 30, 2024Sep 17, 2024AGMA.G.M.
              Aug 14, 2024Aug 06, 2024Board MeetingQuarterly Results

            • Dividend announcements are not available.

            • No other corporate actions details are available.

            About Parmax Pharma

            Parmax Pharma Ltd., incorporated in the year 1994, is a Small Cap company (having a market cap of Rs 15.27 Crore) operating in Pharmaceuticals sector. Parmax Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Job Work, Freight for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • UA

              Umang Alkesh Gosalia

              Managing Director
              AR

              Ami R Shah

              Independent Director
              NS

              Nikhil S Uchat

              Independent Director
              KD

              Keyur D Vora

              Chief Financial Officer
              Show More
            • B A Shah S R Mehta & Co.
              B A Shah & Associates

            Industry

            Pharma - Indian

            Key Indices Listed on

            -

            Address

            Plot No. 20, Survey No. 52,Rajkot-Gondal National Highway No. 27,Rajkot, Gujarat - 360311

            Contact

            [email protected]

            http://www.parmaxpharma.com

            More Details

            FAQs about Parmax Pharma share

            • 1. What's the Parmax Pharma share price today?
              Parmax Pharma share price is Rs 40.81 as on 25 Jun, 2025, 03:30 PM IST. Parmax Pharma share price is remain unchanged by 0.00% based on previous share price of Rs. 38.02.
            • 2. What's the market capitalization of Parmax Pharma?
              Market Capitalization of Parmax Pharma stock is Rs 15.27 Cr.
            • 3. What is the PE & PB ratio of Parmax Pharma?
              The PE ratio of Parmax Pharma stands at -7.36, while the PB ratio is -9.22.
            • 4. What is Parmax Pharma's 52 week high / low?
              Parmax Pharma share price saw a 52 week high of Rs 55.02 and 52 week low of Rs 28.70.
            • 5. What are the returns for Parmax Pharma share?
              Return Performance of Parmax Pharma Shares:
              • 1 Week: Parmax Pharma share price moved up by 18.29%
              • 3 Month: Parmax Pharma share price moved down by 4.98%
              • 6 Month: Parmax Pharma share price moved down by 1.28%

            Trending in Markets

            Top Gainers As on 03:58 PM | 25 Jun 2025

            Kirloskar Bros.2,161.00
            303.60 (16.35%)
            Network18 Media61.82
            8.17 (15.21%)
            Ibull Housing Fin143.50
            18.82 (15.10%)
            Endurance Tech.2,756.00
            248.91 (9.93%)
            KNR Constructions230.68
            18.50 (8.72%)

            Top Losers As on 03:59 PM | 25 Jun 2025

            GRSE3,003.10
            -179.71 (-5.65%)
            Data Patterns (India)2,790.60
            -144.00 (-4.91%)
            Angel One2,861.30
            -96.00 (-3.25%)
            BEL406.05
            -12.45 (-2.98%)
            Mazagon Dock Ship3,192.70
            -88.71 (-2.71%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Parmax Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »